Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]

ASCO GU 2015 news roundup

Peter Goodwin - ecancer correspondent, London, UK

ASCO GU 2015 news roundup ( Peter Goodwin - ecancer correspondent, London, UK )

Taxane response in prostate cancer may not be influenced by androgen receptor...

Dr Emmanuel Antonarakis - Johns Hopkins School of Medicine, Baltimore, USA

Taxane response in prostate cancer may not be influenced by androgen receptor variations ( Dr Emmanuel Antonarakis - Johns Hopkins School of Medicine, Baltimore, USA )

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal...

Dr Naomi Balzer-Haas - ECOG-ACRIN Cancer Research Group, Philadelphia, USA

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma ( Dr Naomi Balzer-Haas - ECOG-ACRIN Cancer Research Group, Philadelphia, USA )

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in...

Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma ( Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK )

Expert commentary on emerging research in genitourinary cancer

Dr Chris Parker - The Royal Marsden Hospital, London, UK

Expert commentary on emerging research in genitourinary cancer ( Dr Chris Parker - The Royal Marsden Hospital, London, UK )

Combination of dalantercept plus axitinib versus placebo plus axitinib in...

Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma ( Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA )

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic...

Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer ( Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France )

VEGF targeted therapy and chemo an active combination in rapidly progressive...

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

Impact of statins on survival outcomes in metastatic renal cell carcinoma

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

Impact of statins on survival outcomes in metastatic renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

Genomic profiling may reveal new drug targets in urothelial carcinoma

Dr Jeffrey Ross - Albany Medical College, Albany, USA

Genomic profiling may reveal new drug targets in urothelial carcinoma ( Dr Jeffrey Ross - Albany Medical College, Albany, USA )

Combination of abiraterone and cabazitaxel in metastatic castration-resistant...

Dr Joaquin Mateo - Institute of Cancer Research, London, UK

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer ( Dr Joaquin Mateo - Institute of Cancer Research, London, UK )

Management after radical prostatectomy: early adjuvant radiotherapy or wait-and...

Dr Mohammad Parvez Shaikh - Loyola University Medical Centre, Maywood, USA

Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see? ( Dr Mohammad Parvez Shaikh - Loyola University Medical Centre, Maywood, USA )

More from ecancer